Cancer is considered to be a multifactorial disease in which a host cell is transformed from normal to malignant as a result of complex interactions of external (environmental) stimuli and cancer-predisposing or cancer-suppressing genes. Although certain chemical carcinogens and ionizing radiation are known to cause specific alterations at the level of the gene, other correlations are less clear. Not infrequently, cancer is found to aggregate in families in an apparently nonrandom fashion. It has been through the study of such families that our understanding of the genetic events leading to cancer has developed. Both common and rare tumors may occur together in familial-cancer families. Frequently, tumors occur at an earlier age than one would expect in the general population; often, multiple tumors of different organs develop in a particular affected family member. Recent advances in the genetics of familial cancer syndromes have led to the possibility to perform genetic testing on unaffected relatives who might carry a genetic defect that predisposes them to cancer. Complex ethical, social, and legal implications arise from these new technical advances.
. Heritable germline mutations of the p53 tumor suppressor gene have been described in probands of Li-Fraumeni syndrome families and both affected and young unaffected relatives (5, 6) . In addition, occasional germline p53 mutations have been described in patients not belonging to Li-Fraumeni kindreds but who have multifocal osteogenic sarcoma, multiple primary malignancies, and to a very much lesser degree, breast cancer. Several studies are ongoing in other populations of cancer patients to determine the genetic heterogeneity of Li-Fraumeni syndrome, and the high-risk cancer populations likely to harbor a genetic predisposition to the cancers they develop.
The very high probability of developing cancer in individuals, and in particular children, who carry germline alterations of tumor suppressor genes has led to the possibility of predictive genetic testing in unaffected relatives. It is now technically feasible to perform such testing in many molecular biology laboratories worldwide. However, with the imminent identification of many more genes for hereditary diseases, including cancer, many of which will directly affect children, the proper use of the genetic information in both individuals and the population is a matter of growing concern. Many issues, such as autonomy, confidentiality, and nondiscrimination, are generic to testing for any heritable disease. For adult-onset genetic disorders such as Huntington's or Alzheimer's disease, the issue of testing children is less frequently found to be at issue. However, for diseases such as cancer, for which primary preventive measures may be available, predictive testing of children raises important concerns (7, 8) .
One of the most widely discussed and evaluated testing "programs" has been that ofp53 testing in high-risk patients, including those who belong to classic Li There are many gaps in our knowledge of the role of genetic predisposition in cancer development, and many drawbacks of predictive testing as it is currently available. Nonetheless, the possibility of reducing the marked loss of human potential resulting from the death of a child or young adult makes pilot research efforts for early intervention in carriers of germline mutations of cancer-predisposing genes worthwhile. Further studies into the development of more accurate testing procedures, understanding of the effect of germline mutations on cell transformation and tumor formation, and perhaps the development of animal models will continue to be important. In addition, studies of evaluation of cancer risk notification addressing this process, the impact of knowledge, attitudes, emotions, and disease and health status outcomes are required (10) . Ultimately, one would hope that these studies lead through screening to the early detection and successful treatment of cancer in children and young adults.
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